GILD34 Stock Overview
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Notes are coming soon
Gilead Sciences, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$216.04|
|52 Week High||US$235.55|
|52 Week Low||US$132.24|
|1 Month Change||-1.28%|
|3 Month Change||23.57%|
|1 Year Change||17.23%|
|3 Year Change||62.64%|
|5 Year Change||67.52%|
|Change since IPO||19.49%|
Recent News & Updates
|GILD34||BR Biotechs||BR Market|
Return vs Industry: GILD34 exceeded the BR Biotechs industry which returned -0.8% over the past year.
Return vs Market: GILD34 exceeded the BR Market which returned -8.5% over the past year.
|GILD34 Average Weekly Movement||6.2%|
|Biotechs Industry Average Movement||9.9%|
|Market Average Movement||6.6%|
|10% most volatile stocks in BR Market||10.4%|
|10% least volatile stocks in BR Market||3.2%|
Stable Share Price: GILD34 is not significantly more volatile than the rest of BR stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: GILD34's weekly volatility (6%) has been stable over the past year.
About the Company
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients.
Gilead Sciences, Inc. Fundamentals Summary
|GILD34 fundamental statistics|
Is GILD34 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GILD34 income statement (TTM)|
|Cost of Revenue||US$5.64b|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||2.66|
|Net Profit Margin||12.29%|
How did GILD34 perform over the long term?See historical performance and comparison